Today’s article is all about the CRSP stock; if you have had an interest in investing in the CRSP stock or you want to, then you have come to the right page; this article will provide you with a good insight on the Crispr stock alongside with its stock forecast for 2023 – 2030.
The CRSP therapies are one of the most transformative and potentially powerful technologies in human history. None of the CRISPR-based therapeutics have been indicated for treating human diseases, but 3 leading companies are racing to bring these therapies to the clinic.
The 3-leading gene-editing companies looking at commercializing CRISPR-based therapeutics are Intellia Therapeutics, CRISPR Therapeutics, and Editas Medicine.
What Is CRISPR stock?
CRSP Therapeutics is a gene-editing company that focuses on developing transformative gene-based medicines for acute diseases using its proprietary Cas9 platform. Cas9 is a revolutionary gene-editing technology that allows for directed changes to genomic DNA.
CRISPR Therapeutics has established a portfolio of therapeutic programs across many disease areas, including regenerative medicine, hemoglobinopathies, oncology, and rare diseases. CRISPR Therapeutics has collaborated with companies including Vertex Pharmaceuticals, Bayer, and ViaCyte, Inc. to expand and accelerate its efforts.
The CRISPR company is headquartered in Zug, Switzerland, with its wholly owned United States. subsidiary, R&D operations, and CRISPR Therapeutics, Inc., based in Cambridge, Massachusetts. It has different business offices in California, London, and San Francisco, United Kingdom.
The CRISPR Therapeutics company has the largest market capitalization of the 3, at $10.9B, with a clinical development program that is more advanced than Editas and Intellia. CRISPR Therapeutics has already published promising data on the use of its product in sickle cell and β-thalassemia disease in the New England Journal of Medicine.
The CRISPR company has also started its early-stage clinical trials for its immuno-oncology program, which is based on developing allogeneic CAR-T (chimeric antigen receptor T) cells targeting well-characterized targets in hematological malignancies, such as B cell maturation agent and as CD19+.
The development of allogeneic chimeric antigen receptor T (CAR-T) cells may circumvent the costs and manufacturing associated with autologous CAR-T cells, which have already demonstrated impressive, durable responses in patients with hematological malignancies.
Furthermore, the CRISPR Therapeutics company was co-founded by Dr. Emmanuelle Charpentier, who won the Nobel Prize in Chemistry 2020 for CRISPR-Cas9, whose expertise will support the successful direction of the company’s R&D programs.
Dr. Jennifer A. Doudna was the other joint winner of the Nobel Prize in Chemistry 2020, and she co-founded Intellia. Intellia’s approaches to clinical development can be separated into ex vivo and in vivo. In vivo explains the introduction of the CRSP technology into the patient via an intravenous route of administration. In contrast, ex vivo explains the removal of stem cells for gene editing coupled with re-introducing these repaired cells into the patient.
Intellia’s NTLA-2001 uses an in vivo approach to tackling rare cases of hereditary disorder, transthyretin amyloidosis, for which only chronic treatment options are available. Like CRISPR Therapeutics, Intellia considers sickle cell disease as a target indication. Still, the company is behind CRISPR Therapeutics in clinical development, indicating a future second-to-market disadvantage.
The Intellia company has established high-profile collaborations with Novartis and Regeneron, which will boost the company’s ability to navigate a successful market route and provide the company with the necessary experience and infrastructure in drug development and commercialization.
The Editas Medicine company has the smallest market capitalization of the 3 and currently has a single agent in clinical development: EDIT-101. Unlike the other 2 companies listed above, Editas is focused on ocular diseases, specifically Leber Congenital Amaurosis, which indicates the potential to monopolize this space.
Dr. Fen Zhang, the co-founder of Editas, is an expert in optogenetics and a pioneer in applying the CRISPR-Cas9 system in cells (human cells), both of which represent the key strengths for Editas’ to achieve its vision.
Each company has distinct and overlapping target indications, and all 3 are developing an immuno-oncology program and targeting hematological disorders, either in the pre-clinical or clinical stages. This fact suggests potential future competition but also indicates that each of the 3 companies has room to carve out and monopolize distinct markets.
The CRISPR Therapeutics company has a head start regarding its clinical development and raising cap and represents an excellent choice for investors. However, each of these companies also produces little to no revenue. The current expectations are contingent on favorable results from their upcoming clinical trials, which are still in the early stages of development.
Is Crispr Stock a Good Investment?
The potential for CRISPR technology is “BIG.” The oncology drugs can prolong life from months to years, while CRISPR-based therapeutics show a potential cure and could prolong life for decades.
The potential upside for long-term investors and patients is huge. While CRISPR-based therapies are still in the development stage, they will inevitably transform the lives of many patients and the shape of the industry if they are finally brought to market.
Crispr Stock Forecast 2023
In the CRISPR Therapeutics AG forecast for 2023, twelve predictions are offered for each month, with an average CRISPR stock forecast of $90.74, a high stock forecast of $100.06, and a low stock forecast of $82.83.
The average stock CRISPR stock forecast for 2023 represents a +18.3% increase from the last price of $76.6999969482422.
Crispr Stock Forecast 2024
In the forecast on the CRISPR Therapeutics AG stock for 2024, twelve predictions are offered for each month, with an average CRISPR stock forecast of $113.41, a high stock forecast of $121.85, and a low stock forecast of $104.72.
The average stock CRISPR stock forecast for 2024 represents a +47.86% increase from the last price of $76.6999969482422.
Crispr Stock Forecast 2025
In the CRISPR Therapeutics AG forecast for 2025, twelve predictions are offered for each month:
- An average stock forecast of $136.82
- A high stock forecast of $142.87
- A low stock forecast of $125.08
The average CRISPR stock forecast for 2025 represents a +78.38 percent increase from the last price of $76.6999969482422.
Read Also:
Li Auto Stock Price Forecast for 2023, 2025 & 2027
Teladoc Stock Forecast 2023 – 2025 -2030
Grow Generation Corp – GRWG Stock Forecast 2023 – 2025 – 2030
Crispr Stock Forecast 2026
In the forecast on the CRISPR Therapeutics AG stock for 2026, twelve predictions are offered for each month, with an average CRISPR stock forecast of $147.76, a high stock forecast of $150.41, and a low stock forecast of $144.16.
The average stock CRISPR stock forecast for 2026 represents a +92.65% increase from the last price of $76.6999969482422.
Crispr Stock Forecast 2027
In the forecast on the CRISPR Therapeutics AG stock for 2027, twelve predictions are offered for each month of 2027, with an average stock forecast of $148.08 and a high stock forecast of $151.13 and a low stock forecast of $142.04.
The average CRISPR stock forecast for 2027 represents a +93.06 percent increase from the last price of $76.6999969482422.
Crispr Stock Forecast 2028
In the forecast on the CRISPR Therapeutics AG stock for 2028, twelve predictions are offered for each month, with an average CRISPR stock forecast of $117.7, a high stock forecast of $138.33, and a low stock forecast of $108.29.
The average stock CRISPR stock forecast for 2028 represents a +53.46% increase from the last price of $76.6999969482422.
Crispr Stock Forecast 2029
In the forecast on the CRISPR Therapeutics AG stock for 2029, twelve predictions are offered for each month, with an average CRISPR stock forecast of $111.03, a high stock forecast of $115.67, and a low stock forecast of $100.31.
The average stock CRISPR stock forecast for 2023 represents a +44.76% increase from the last price of $76.6999969482422.
Crispr Stock Forecast 2030
In the forecast on the CRISPR Therapeutics AG stock for 2030, twelve predictions are offered for each month, with an average CRISPR stock forecast of $101.01, a high stock forecast of $108.31, and a low stock forecast of $96.12.
The average CRISPR stock forecast for 2030 represents a +31.7 percent increase from the last price of $76.6999969482422.
Is CRSP Stock a Long-Term Investment?
CRISPR Therapeutics AG stock can be a good investment choice for investors. According to AI Pickup, the CRISPR Therapeutics AG stock price forecast for 2023 Aug. is $76.7135544501719
FAQS
Will CRSP Stock go up?
In the forecast on the CRISPR Therapeutics AG stock for 2023, five predictions are offered for each month with an average stock forecast of $78.81, a high stock forecast of $81.31, and a low stock forecast of $76.71. The average stock forecast for 2023 represents a +2.74 percent increase from the last price of $76.6999969482422.
Is CRSP a Buy, Sell or Hold?
The consensus among 14 Wall Street analysts covering the CRSP stock is to Buy CRSP stock.
Is Crispr undervalued?
Valuation metrics show that the CRISPR stock may be overvalued, and its Value Score of D indicates it might not be the best pick for value investors.
What is the target price for CRSP?
High
- $220.00
Median
- $103.50
Low
- $50.00
Average
- $112.41
Current Price
- $71.74
Is CRSP a good buy now?
The potential for CRISPR technology is “BIG.” The oncology drugs can prolong life from months to years, while CRISPR-based therapeutics show a potential cure and could prolong life for decades.
Why is CRSP dropping?
According to data given by the S&P Global Market Intelligence. After surging roughly 151% across 2020’s trading, investors reassessed the gene-editing specialist’s drug pipeline and moved out of the company’s stock.
What’s going on with Crispr?
CRISPR Gene Editing Can Cause Unwanted Changes in Human Embryos, Study Finds. Instead of addressing genetic mutations, the Crispr machinery prompted cells to lose entire chromosomes.
The current trials using CRISPR-based treatments are still in the early stages. That means that even if the treatments are safe and effective, they are likely still a few years away from FDA approval and are broadly available to patients.
Conclusion
As I earlier said, The CRSP therapies are one of the most transformative and potentially powerful technologies in human history. None of the CRISPR-based therapeutics have been indicated for treating human diseases, but 3 leading companies are racing to bring these therapies to the clinic.
According to our forecast, the CRSP stock has the potential to rise, and we all know that nothing comes easily and as an investor taking risks is part of the game.
Watch the Video Below:
About Author
